JP2012510457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510457A5 JP2012510457A5 JP2011538050A JP2011538050A JP2012510457A5 JP 2012510457 A5 JP2012510457 A5 JP 2012510457A5 JP 2011538050 A JP2011538050 A JP 2011538050A JP 2011538050 A JP2011538050 A JP 2011538050A JP 2012510457 A5 JP2012510457 A5 JP 2012510457A5
- Authority
- JP
- Japan
- Prior art keywords
- der
- amb
- bla
- cla
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002009 allergen Effects 0.000 claims 22
- 241000287523 Ara Species 0.000 claims 12
- 235000018102 proteins Nutrition 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 241000196324 Embryophyta Species 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 5
- 108091007172 antigens Proteins 0.000 claims 5
- 102000038129 antigens Human genes 0.000 claims 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- 239000000428 dust Substances 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N 3-Mercaptopropane-1,2-diol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 229940035024 thioglycerol Drugs 0.000 claims 3
- WZXXZHONLFRKGG-UHFFFAOYSA-N 2,3,4,5-tetrachlorothiophene Chemical compound ClC=1SC(Cl)=C(Cl)C=1Cl WZXXZHONLFRKGG-UHFFFAOYSA-N 0.000 claims 2
- 208000002552 Acute Disseminated Encephalomyelitis Diseases 0.000 claims 2
- 201000004304 Addison's disease Diseases 0.000 claims 2
- 241000223602 Alternaria alternata Species 0.000 claims 2
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 claims 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 2
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 2
- 206010002967 Aplastic anaemia Diseases 0.000 claims 2
- 235000017060 Arachis glabrata Nutrition 0.000 claims 2
- 240000005781 Arachis hypogaea Species 0.000 claims 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims 2
- 235000018262 Arachis monticola Nutrition 0.000 claims 2
- 240000003325 Artemisia Species 0.000 claims 2
- 235000003826 Artemisia Nutrition 0.000 claims 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims 2
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 241000219495 Betulaceae Species 0.000 claims 2
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 2
- 241000238657 Blattella germanica Species 0.000 claims 2
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims 2
- 235000014653 Carica parviflora Nutrition 0.000 claims 2
- 244000132059 Carica parviflora Species 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 244000281762 Chenopodium ambrosioides Species 0.000 claims 2
- 206010009839 Coeliac disease Diseases 0.000 claims 2
- 206010011401 Crohn's disease Diseases 0.000 claims 2
- 108010055622 Dermatophagoides farinae antigen f 1 Proteins 0.000 claims 2
- 108010082995 Dermatophagoides farinae antigen f 2 Proteins 0.000 claims 2
- 108010082990 Dermatophagoides farinae antigen f 7 Proteins 0.000 claims 2
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 claims 2
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 claims 2
- 108010061638 Dermatophagoides pteronyssinus antigen p 7 Proteins 0.000 claims 2
- 102000012288 EC 4.2.1.11 Human genes 0.000 claims 2
- 108010022181 EC 4.2.1.11 Proteins 0.000 claims 2
- 241000282324 Felis Species 0.000 claims 2
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000003807 Graves Disease Diseases 0.000 claims 2
- 201000004779 Graves' disease Diseases 0.000 claims 2
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 2
- 101700014388 HCH1 Proteins 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 201000007313 Kawasaki disease Diseases 0.000 claims 2
- 210000000265 Leukocytes Anatomy 0.000 claims 2
- 206010025135 Lupus erythematosus Diseases 0.000 claims 2
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 claims 2
- 206010028417 Myasthenia gravis Diseases 0.000 claims 2
- 102100002315 NUTF2 Human genes 0.000 claims 2
- 101710040036 NUTF2 Proteins 0.000 claims 2
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 206010034695 Pernicious anaemia Diseases 0.000 claims 2
- 206010036030 Polyarthritis Diseases 0.000 claims 2
- 102000011195 Profilins Human genes 0.000 claims 2
- 108050001408 Profilins Proteins 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims 2
- 206010038294 Reiter's syndrome Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 240000001744 Salsola kali Species 0.000 claims 2
- 235000007658 Salsola kali Nutrition 0.000 claims 2
- 235000015076 Shorea robusta Nutrition 0.000 claims 2
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 2
- 102100018690 TPT1 Human genes 0.000 claims 2
- 101700073473 TPT1 Proteins 0.000 claims 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 2
- 206010043207 Temporal arteritis Diseases 0.000 claims 2
- 206010043778 Thyroiditis Diseases 0.000 claims 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 2
- 231100000765 Toxin Toxicity 0.000 claims 2
- 102000004142 Trypsin Human genes 0.000 claims 2
- 108090000631 Trypsin Proteins 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000000961 alloantigen Effects 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 235000003484 annual ragweed Nutrition 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 235000009052 artemisia Nutrition 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 101700002556 bet Proteins 0.000 claims 2
- 230000003115 biocidal Effects 0.000 claims 2
- 235000018185 birch Nutrition 0.000 claims 2
- 235000018212 birch Nutrition 0.000 claims 2
- 235000006263 bur ragweed Nutrition 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 235000003488 common ragweed Nutrition 0.000 claims 2
- 108060003523 dnaK Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 230000002538 fungal Effects 0.000 claims 2
- 229940079866 intestinal antibiotics Drugs 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 102000027675 major histocompatibility complex family Human genes 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 2
- 235000020232 peanut Nutrition 0.000 claims 2
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 2
- 235000009736 ragweed Nutrition 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 108020003112 toxins Proteins 0.000 claims 2
- 229960001322 trypsin Drugs 0.000 claims 2
- 239000012588 trypsin Substances 0.000 claims 2
- 206010004161 Basedow's disease Diseases 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 206010010329 Congenital anaemia Diseases 0.000 claims 1
- 210000004392 Genitalia Anatomy 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000007475 Hemolytic Anemia Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 230000002949 hemolytic Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
Claims (23)
- 少なくとも1つの遊離したシステイン残基を含み、８〜３０アミノ酸長のペプチドを少なくともひとつ含む安定な凍結乾燥組成物の製造方法であって、以下の工程を含む製造方法：
（a）（i）非還元性炭水化物としてトレハロースのみ、（ii）チオグリセロールおよび（iii）少なくとも1つの前記ペプチド、を溶液中に含む組成物を調製すること；ならびに
（b）工程（a）によって生じる組成物を凍結乾燥すること。 - 前記組成物が、（a）チオグリセロールが、少なくとも1つの遊離したシステイン残基を含む組成物のペプチド成分のモル濃度より60〜80倍高いモル濃度で存在する工程（a）で調製される請求項１に記載の方法。
- 前記組成物が、（a）チオグリセロールが、少なくとも1つの遊離したシステイン残基を含む組成物のペプチド成分のモル濃度より30〜40倍高いモル濃度で存在する工程（a）で調製される請求項１に記載の方法。
- 少なくとも1つのペプチドがアレルゲンまたは同種抗原に由来する少なくとも1つのMHC結合性T細胞エピトープを含む領域を含む、請求項１〜３のいずれか1項に記載の方法。
- エピトープが、
a）植物アレルゲン、動物鱗屑アレルゲン、カビアレルゲンもしくは真菌アレルゲン、粉塵アレルゲン、抗生物質もしくは他の薬物、刺咬昆虫毒、環境アレルゲンまたは食物アレルゲンから選択されるアレルゲン；あるいは
b）急性播種性脳脊髄炎、アジソン病、強直性脊椎炎、抗リン脂質抗体症候群、再生不良性貧血、自己免疫性肝炎、自己免疫性卵巣炎、セリアック病、クローン病、1型糖尿病、妊娠性類天疱瘡、グッドパスチャー症候群、グレーブス病、ギラン・バレー症候群、橋本病、特発性血小板減少性紫斑病、川崎病、エリテマトーデス、多発性硬化症、重症筋無力症、ナルコレプシー、オプソクローヌス・ミオクローヌス症候群、視神経炎、オード甲状腺炎、天疱瘡、悪性貧血、イヌの多発性関節炎、原発性胆汁性肝硬変、関節リウマチ、ライター症候群、シェーグレン症候群、高安動脈炎、側頭動脈炎、温式自己免疫性溶血性貧血またはヴェゲナー肉芽腫症と関連する主要抗原から選択される抗原
に由来する、請求項４に記載の方法。 - 植物アレルゲンがイネ科植物アレルゲンである請求項５の方法。
- エピトープが、ネコ鱗屑タンパク質Fel d1；チリダニタンパク質Der p 1、Der p 2、Der p 7、Der p 3〜15、Der p 18、Der p 20、Der p 21およびDer p 23、Der f 1、Der f 2、Der f 7、Der f 10、Der f 11〜18およびDer f 20〜22；ブタクサタンパク質amb a 1、amb a 2、amb a 3、amb a 5、amb a 6、amb a 7、amb a 8、amb a 9、およびamb a 1.1、amb a 1.2、amb a1.3またはamb a1.4を含むこれらのアイソフォーム；ドクムギタンパク
質lol p1およびlol p5；オオアワガエリタンパク質phl p1およびphl p5；ギョウギシバタンパク質Cyn d 5；アルテルナリア・アルテルナータ（Alternaria alternata）タンパク
質Alt a 1、Alt a 2、Alt a 3〜Alt a 10、Alt a 12、Alt a 13およびエノラーゼ（Alt a
6）、Cla h 1、Cla h 2、Cla h 5〜10、Cla h 12、Cla h GST、Cla h HCh1、Cla h HSP70、Cla h NTF2、Cla h TCTP；カバノキタンパク質Bet v1、Bet v2、Bet v3、Bet v4、Bet
v6、Bet v7、Bet v8およびP14；チャバネゴキブリタンパク質Bla g 1、Bla g 2、Bla g 3、Bla g 4、Bla g 5およびBla g 6、Bla g 7、Bla g 8、Bla g 9、Bla g GSTD1、Bla g トリプシン；ヨモギタンパク質Art v 1；ロシアアザミタンパク質Sal k 1、Sal k 2およ
びSal k 8；ピーナッツAra h1、Ara h2、Ara h3、Ara h4、Ara h5、Ara h6、植物プロフィリンもしくは脂質輸送タンパク質、またはヒト白血球抗原、に由来している、請求項５に記載の方法。 - 少なくとも1種のペプチドが、配列番号1〜58のいずれかの配列を含むか、または該配列からなる、請求項７に記載の方法。
- 組成物が配列番号1〜4のペプチドを含む、請求項８に記載の方法。
- 組成物が、配列番号84〜86のペプチドをさらに含み、任意にさらなるペプチドを含まない、請求項９に記載の方法。
- 請求項１〜１０のいずれか１項に記載の方法により製造される安定な凍結乾燥組成物。
- 請求項１１に記載の安定な凍結乾燥組成物を再構成する方法であって、該凍結乾燥組成物は溶液中で再構成する工程を含む方法。
- 請求項１２に記載の方法により再構成された溶液。
- 寛容化または免疫化のための少なくとも1つのペプチドを含む安定な凍結乾燥組成物であって、さらにチオグリセロール、および非還元性炭水化物としてトレハロースのみを含み、該ペプチドは8〜30アミノ酸長のものであり、少なくとも1つの遊離したシステイン残基を含む、組成物
- 少なくとも1つのペプチドがアレルゲンまたは同種抗原に由来する少なくとも1つのMHC結合性T細胞エピトープを含む領域を含む、請求項１４に記載の組成物。
- エピトープが、
（a）植物アレルゲン、動物鱗屑アレルゲン、カビアレルゲンもしくは真菌アレルゲン、粉塵アレルゲン、抗生物質もしくは他の薬物、刺咬昆虫毒、環境アレルゲンまたは食物アレルゲンから選択されるアレルゲン；あるいは
（b）急性播種性脳脊髄炎、アジソン病、強直性脊椎炎、抗リン脂質抗体症候群、再生不良性貧血、自己免疫性肝炎、自己免疫性卵巣炎、セリアック病、クローン病、1型糖尿病、妊娠性類天疱瘡、グッドパスチャー症候群、グレーブス病、ギラン・バレー症候群、橋本病、特発性血小板減少性紫斑病、川崎病、エリテマトーデス、多発性硬化症、重症筋無力症、ナルコレプシー、オプソクローヌス・ミオクローヌス症候群、視神経炎、オード甲状腺炎、天疱瘡、悪性貧血、イヌの多発性関節炎、原発性胆汁性肝硬変、関節リウマチ、ライター症候群、シェーグレン症候群、高安動脈炎、側頭動脈炎、温式自己免疫性溶血性貧血またはヴェゲナー肉芽腫症と関連する主要抗原から選択される抗原
に由来する、請求項１５に記載の組成物。 - 植物アレルゲンがイネ科植物アレルゲンである請求項５の方法。
- エピトープが、ネコ鱗屑タンパク質Fel d1；チリダニタンパク質Der p 1、Der p 2、Der p 7、Der p 3〜15、Der p 18、Der p 20、Der p 21およびDer p 23、Der f 1、Der f 2、Der f 7、Der f 10、Der f 11〜18およびDer f 20〜22；ブタクサタンパク質amb a 1、amb a 2、amb a 3、amb a 5、amb a 6、amb a 7、amb a 8、amb a 9、およびamb a 1.1、amb a 1.2、amb a1.3またはamb a1.4を含むこれらのアイソフォーム；ドクムギタンパク
質lol p1およびlol p5；オオアワガエリタンパク質phl p1およびphl p5；ギョウギシバタンパク質Cyn d 5；アルテルナリア・アルテルナータ（Alternaria alternata）タンパク
質Alt a 1、Alt a 2、Alt a 3〜Alt a 10、Alt a 12、Alt a 13およびエノラーゼ（Alt a
6）、Cla h 1、Cla h 2、Cla h 5〜10、Cla h 12、Cla h GST、Cla h HCh1、Cla h HSP70、Cla h NTF2、Cla h TCTP；カバノキタンパク質Bet v1、Bet v2、Bet v3、Bet v4、Bet
v6、Bet v7、Bet v8およびP14；チャバネゴキブリタンパク質Bla g 1、Bla g 2、Bla g 3、Bla g 4、Bla g 5およびBla g 6、Bla g 7、Bla g 8、Bla g 9、Bla g GSTD1、Bla g トリプシン；ヨモギタンパク質Art v 1；ロシアアザミタンパク質Sal k 1、Sal k 2およ
びSal k 8；ピーナッツAra h1、Ara h2、Ara h3、Ara h4、Ara h5、Ara h6、植物プロフィリンもしくは脂質輸送タンパク質、またはヒト白血球抗原、に由来している、請求項１６に記載の組成物。 - 少なくとも1つのペプチドが、配列番号1〜58のいずれかの配列を含むか、または該配列からなる、請求項１８に記載の組成物。
- 配列番号1〜4のペプチドを含む、請求項１９に記載の組成物。
- 配列番号84〜86のペプチドをさらに含み、任意にさらなるペプチドを含まない、請求項２０に記載の組成物。
- 請求項１４〜２１のいずれか１項に記載の安定な凍結乾燥組成物を再構成する方法であって、該凍結乾燥組成物は溶液中で再構成する工程を含む方法。
- 請求項２２に記載の方法により再構成された溶液。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0821806.7 | 2008-11-28 | ||
| GBGB0821806.7A GB0821806D0 (en) | 2008-11-28 | 2008-11-28 | Compositions with reduced dimer formation |
| PCT/GB2009/002767 WO2010061193A2 (en) | 2008-11-28 | 2009-11-27 | Compositions with reduced dimer formation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014180264A Division JP5905942B2 (ja) | 2008-11-28 | 2014-09-04 | 二量体形成の減少した組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012510457A JP2012510457A (ja) | 2012-05-10 |
| JP2012510457A5 true JP2012510457A5 (ja) | 2013-01-24 |
| JP5612592B2 JP5612592B2 (ja) | 2014-10-22 |
Family
ID=40262373
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538050A Expired - Fee Related JP5612592B2 (ja) | 2008-11-28 | 2009-11-27 | 二量体形成の減少した組成物 |
| JP2014180264A Expired - Fee Related JP5905942B2 (ja) | 2008-11-28 | 2014-09-04 | 二量体形成の減少した組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014180264A Expired - Fee Related JP5905942B2 (ja) | 2008-11-28 | 2014-09-04 | 二量体形成の減少した組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9180098B2 (ja) |
| EP (2) | EP2649990A1 (ja) |
| JP (2) | JP5612592B2 (ja) |
| KR (1) | KR101669693B1 (ja) |
| CN (1) | CN102227214B (ja) |
| AU (1) | AU2009321358B2 (ja) |
| BR (1) | BRPI0921541A2 (ja) |
| CA (1) | CA2744587C (ja) |
| DK (1) | DK2373293T3 (ja) |
| EA (1) | EA019923B1 (ja) |
| ES (1) | ES2427855T5 (ja) |
| GB (2) | GB0821806D0 (ja) |
| HK (1) | HK1161139A1 (ja) |
| HR (1) | HRP20130933T1 (ja) |
| IL (1) | IL213088A (ja) |
| MX (1) | MX2011005530A (ja) |
| NZ (1) | NZ593145A (ja) |
| PL (1) | PL2373293T3 (ja) |
| SG (1) | SG171438A1 (ja) |
| SI (1) | SI2373293T1 (ja) |
| WO (1) | WO2010061193A2 (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| EP2793939A1 (en) * | 2011-12-23 | 2014-10-29 | Novartis AG | Stable compositions for immunising against staphylococcus aureus |
| GB201208293D0 (en) | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
| GB201209862D0 (en) | 2012-06-01 | 2012-07-18 | Circassia Ltd | Cladosporium peptides |
| GB201209868D0 (en) * | 2012-06-01 | 2012-07-18 | Circassia Ltd | Alternaria peptides |
| EP2698162A1 (en) * | 2012-08-15 | 2014-02-19 | Credentis AG | Method for producing a composition for treating a tooth lesion |
| EP3964232A1 (en) | 2012-10-30 | 2022-03-09 | Aravax Pty Ltd | Novel immunotherapeutic molecules and uses thereof |
| GB201301457D0 (en) * | 2013-01-28 | 2013-03-13 | Fluorogenics Ltd | Freeze-dried composition |
| CN103040769A (zh) * | 2013-02-05 | 2013-04-17 | 南京碧迪可医药科技有限公司 | 一种稳定的诺卡沙星粉针冻干剂 |
| BR112016006813A2 (pt) | 2013-09-25 | 2017-09-19 | Aravax Pty Ltd | Composição imunoterapêutica nova e seus usos |
| CN103656635B (zh) * | 2013-12-05 | 2016-05-18 | 安徽润敏江生物科技有限公司 | 一种德国小蠊过敏原制剂的制备方法 |
| ES2768716T3 (es) * | 2014-04-10 | 2020-06-23 | Asit Biotech S A | Preparación de alérgenos libre de HSP |
| WO2016124661A1 (en) * | 2015-02-04 | 2016-08-11 | Universität Zürich | Use of hla-b27 homodimers for cancer treatment |
| CA3004745A1 (en) | 2015-11-12 | 2017-05-18 | University Of Virginia Patent Foundation | Compositions and methods for vas-occlusive contraception and reversal thereof |
| EP3374396A1 (en) * | 2015-11-13 | 2018-09-19 | The United States of America, as represented by the secretary, Department of Health and Human Services | Anti-bcma polypeptides and proteins |
| CN109562171B (zh) | 2016-08-10 | 2023-10-17 | 苏黎世大学 | MHC Ia类开放型构象异构体 |
| US10751124B2 (en) | 2017-01-05 | 2020-08-25 | Contraline, Inc. | Methods for implanting and reversing stimuli-responsive implants |
| KR102649069B1 (ko) | 2018-05-31 | 2024-03-19 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물 |
| WO2020027466A1 (ko) | 2018-07-28 | 2020-02-06 | 주식회사 엑소코바이오 | 엑소좀의 동결건조 방법 |
| KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
| AU2019380413A1 (en) | 2018-11-13 | 2021-05-20 | Contraline, Inc. | Systems and methods for delivering biomaterials |
| US20240060082A1 (en) * | 2021-01-22 | 2024-02-22 | Syngenta Crop Protection Ag | Soybean Engineered Resistance |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0044532B1 (en) * | 1980-07-18 | 1986-04-23 | E.I. Du Pont De Nemours And Company | Monothioglycerol as thiol-protector in lyophilized materials |
| US4442212A (en) | 1980-11-10 | 1984-04-10 | E. I. Du Pont De Nemours & Company | Monothioglycerol as thiol-protector in lyophilized materials |
| JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| US4855407A (en) | 1985-04-11 | 1989-08-08 | Alpha-1 Biomedicals, Inc. | Solid phase process for synthesizing peptides |
| JP2787162B2 (ja) * | 1989-08-24 | 1998-08-13 | フマキラー株式会社 | 精製ダニアレルゲン |
| EP0500785B1 (en) * | 1989-11-03 | 2002-04-17 | Immulogic Pharmaceutical Corporation | A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor |
| DE69233772D1 (de) | 1991-10-16 | 2009-11-12 | Merck Patent Gmbh | T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe) |
| JPH07507924A (ja) | 1992-04-09 | 1995-09-07 | イミュロジック ファーマスーティカル コーポレイション | アンブロシア・アルテミシフォリア由来の主要アレルゲンのｔ細胞エピトープ |
| US5480972A (en) | 1992-10-30 | 1996-01-02 | The University Of Melbourne | Allergenic proteins from Johnson grass pollen |
| CA2152818A1 (en) | 1992-12-31 | 1994-07-21 | Jay P. Morgenstern | Allergenic proteins and peptides from dog dander and uses therefor |
| JPH10505356A (ja) | 1994-09-02 | 1998-05-26 | イミユロジク・フアーマシユーチカル・コーポレーシヨン | ヒトへの投与のための組成物および方法、抗原特異的免疫応答のダウンレギュレーションを行うことが可能なペプチド |
| DE19508192A1 (de) * | 1995-03-09 | 1996-09-12 | Behringwerke Ag | Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung |
| NZ505324A (en) * | 1997-12-22 | 2002-11-26 | Human Genome Sciences Inc | Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration |
| JP2002500198A (ja) * | 1998-01-09 | 2002-01-08 | サーカシア リミテッド | 脱感作のための方法及び組成物 |
| US7754686B2 (en) * | 2000-08-31 | 2010-07-13 | Novartis Vaccines And Diagnostics, Inc. | Stabilized FGF formulations containing reducing agents |
| ES2351786T3 (es) | 2001-11-13 | 2011-02-10 | Genentech, Inc. | Formulaciones con ligando apo2/trail y usos de las mismas. |
| AU2002347369A1 (en) | 2001-12-05 | 2003-06-17 | Circassia Limited | Immunotherapeutic methods and systems |
| AU2003215524A1 (en) * | 2002-03-15 | 2003-09-29 | Natimmune A/S | Pharmaceutical compositions comprising mannose binding lectin |
| EP1523326A4 (en) | 2002-05-06 | 2009-09-09 | Univ Jefferson | INSULIN-RELATED PEPTIDES HAVING EFFECTS ON BRAIN HEALTH |
| AU2004288854B2 (en) | 2003-11-10 | 2009-10-01 | Arriva-Pharmaceuticals, Inc. | Dry recombinant human alpha 1-antitrypsin formulation |
| US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
| EP1559431B1 (en) | 2003-12-31 | 2007-03-28 | Orthologic Corp. | Pharmaceutical composition for thrombin peptide derivatives |
| JP2007277094A (ja) | 2004-06-29 | 2007-10-25 | Chemo Sero Therapeut Res Inst | 改変ダニ主要アレルゲン含有医薬組成物 |
| US20060029551A1 (en) | 2004-08-05 | 2006-02-09 | Kui Liu | Stable particle formulations of erythropoietin receptor agonists |
| EP1843779A2 (en) | 2005-02-01 | 2007-10-17 | Attenuon, LLC | Compositions containing the anti-angiogenic phscn-peptide |
| NZ561144A (en) * | 2005-03-04 | 2009-09-25 | Dynavax Tech Corp | Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients |
| AU2006299310A1 (en) * | 2005-10-04 | 2007-04-12 | Alk-Abello A/S | Solid vaccine formulation |
| EP1958645A1 (en) * | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
| WO2008115428A2 (en) | 2007-03-16 | 2008-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | A scaleable manufacturing process for cysteine endoprotease b, isoform 2 |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| PL2083856T3 (pl) | 2007-08-15 | 2011-04-29 | Circassia Ltd | Peptydy do odczulania na alergeny |
| GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
-
2008
- 2008-11-28 GB GBGB0821806.7A patent/GB0821806D0/en not_active Ceased
-
2009
- 2009-11-27 EP EP13176176.9A patent/EP2649990A1/en not_active Withdrawn
- 2009-11-27 GB GB1114575.2A patent/GB2479515B/en not_active Expired - Fee Related
- 2009-11-27 JP JP2011538050A patent/JP5612592B2/ja not_active Expired - Fee Related
- 2009-11-27 NZ NZ593145A patent/NZ593145A/xx not_active IP Right Cessation
- 2009-11-27 EA EA201100865A patent/EA019923B1/ru not_active IP Right Cessation
- 2009-11-27 US US13/131,505 patent/US9180098B2/en not_active Expired - Fee Related
- 2009-11-27 BR BRPI0921541A patent/BRPI0921541A2/pt not_active IP Right Cessation
- 2009-11-27 SI SI200930730T patent/SI2373293T1/sl unknown
- 2009-11-27 SG SG2011038718A patent/SG171438A1/en unknown
- 2009-11-27 WO PCT/GB2009/002767 patent/WO2010061193A2/en active Application Filing
- 2009-11-27 CN CN200980147921.8A patent/CN102227214B/zh not_active Expired - Fee Related
- 2009-11-27 KR KR1020117014702A patent/KR101669693B1/ko active IP Right Grant
- 2009-11-27 PL PL09760560T patent/PL2373293T3/pl unknown
- 2009-11-27 EP EP09760560.4A patent/EP2373293B2/en not_active Not-in-force
- 2009-11-27 CA CA2744587A patent/CA2744587C/en not_active Expired - Fee Related
- 2009-11-27 AU AU2009321358A patent/AU2009321358B2/en not_active Ceased
- 2009-11-27 DK DK09760560.4T patent/DK2373293T3/da active
- 2009-11-27 ES ES09760560.4T patent/ES2427855T5/es active Active
- 2009-11-27 MX MX2011005530A patent/MX2011005530A/es active IP Right Grant
-
2011
- 2011-05-24 IL IL213088A patent/IL213088A/en not_active IP Right Cessation
-
2012
- 2012-02-29 HK HK12102043.9A patent/HK1161139A1/xx not_active IP Right Cessation
-
2013
- 2013-10-04 HR HRP20130933AT patent/HRP20130933T1/hr unknown
-
2014
- 2014-09-04 JP JP2014180264A patent/JP5905942B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-06 US US14/876,548 patent/US9375470B2/en active Active
-
2016
- 2016-05-24 US US15/163,211 patent/US20160367660A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012510457A5 (ja) | ||
| HRP20130270T1 (hr) | Peptid s reduciranom formacijom dimera | |
| Flanagan et al. | Sex and gender differences in the outcomes of vaccination over the life course | |
| Wood et al. | Neonatal immunization: where do we stand? | |
| TW202206096A (zh) | 冠狀病毒疫苗 | |
| Schülke et al. | Mouse models for food allergies: where do we stand? | |
| Kunigelis et al. | The dichotomy of tumor exosomes (TEX) in cancer immunity: is it all in the ConTEXt? | |
| JP2023526178A (ja) | コロナウイルスワクチン | |
| JP2012500194A5 (ja) | ||
| Riitho et al. | Bovine pestivirus heterogeneity and its potential impact on vaccination and diagnosis | |
| JP2016519658A5 (ja) | ||
| Saso et al. | Maternal immunization: nature meets nurture | |
| Kametani et al. | Humanized mice as an effective evaluation system for peptide vaccines and immune checkpoint inhibitors | |
| Roesti et al. | Vaccination against amyloidogenic aggregates in pancreatic islets prevents development of type 2 diabetes mellitus | |
| Fernández et al. | Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine | |
| Romano’ et al. | Hepatitis B vaccination: A historical overview with a focus on the Italian achievements | |
| US20200155658A1 (en) | Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with fc-coupled antigens | |
| Wegmann et al. | Synthetic Peptide dendrimers block the development and expression of experimental allergic encephalomyelitis | |
| CN104411818A (zh) | 诱导抗原特异性调节性t细胞的方法 | |
| Tobagus et al. | Adjuvant costimulation during secondary antigen challenge directs qualitative aspects of oral tolerance induction, particularly during the neonatal period | |
| Riccardo et al. | Maternal immunization: new perspectives on its application against non-infectious related diseases in newborns | |
| Abdulla et al. | The role of immunity in the pathogenesis of SARS-CoV-2 infection and in the protection generated by COVID-19 vaccines in different age groups | |
| JP2018522011A5 (ja) | ||
| Omenaca et al. | Hepatitis B response of premature infants after primary and booster immunisation with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/haemophilus influenzae type B vaccine | |
| Wikman et al. | General strategies for efficient adjuvant incorporation of recombinant subunit immunogens |